Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ANIX

ANIX - Anixa Biosciences Inc Stock Price, Fair Value and News

3.56USD-0.21 (-5.57%)Market Closed
Watchlist

Market Summary

USD3.56-0.21
Market Closed
-5.57%

ANIX Stock Price

View Fullscreen

ANIX RSI Chart

ANIX Valuation

Market Cap

112.9M

Price/Earnings (Trailing)

-11.5

Price/Sales (Trailing)

537.39

EV/EBITDA

-12.98

Price/Free Cashflow

-18.18

ANIX Price/Sales (Trailing)

ANIX Profitability

EBT Margin

-4548.42%

Return on Equity

-40.31%

Return on Assets

-38.44%

Free Cashflow Yield

-5.5%

ANIX Fundamentals

ANIX Revenue

Revenue (TTM)

210.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

ANIX Earnings

Earnings (TTM)

-9.8M

Earnings Growth (Yr)

22.61%

Earnings Growth (Qtr)

-7.13%

Breaking Down ANIX Revenue

Last 7 days

-10.2%

Last 30 days

-7.7%

Last 90 days

37.3%

Trailing 12 Months

2.5%

How does ANIX drawdown profile look like?

ANIX Financial Health

Current Ratio

12.5

Debt/Equity

0.07

Debt/Cashflow

-3.54

ANIX Investor Care

Shares Dilution (1Y)

2.51%

Diluted EPS (TTM)

0.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023000210.0K
20220000
2021000512.0K
20200000
2019896.9K681.3K465.6K250.0K
2018550.0K737.5K925.0K1.1M
2017315.6K331.3K346.9K362.5K
20167.0M4.8M2.5M300.0K
20150009.3M
20140000
2013802.2K664.4K526.6K388.9K
20121.4M1.6M1.4M940.0K
2011798.8K866.9K935.1K1.0M
2010000730.7K

Tracking the Latest Insider Buys and Sells of Anixa Biosciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Oct 31, 2023
catelani michael
acquired
3,004
2.69
1,117
president, coo & cfo
Oct 10, 2023
titterton lewis h jr
acquired
41,200
2.575
16,000
-
Jul 31, 2023
kumar amit
sold
-42,126
3.57
-11,800
chief executive officer
Jul 28, 2023
kumar amit
sold (taxes)
-103,001
3.63
-28,375
chief executive officer
Jul 28, 2023
kumar amit
acquired
103,000
2.575
40,000
chief executive officer
Jul 27, 2023
titterton lewis h jr
sold (taxes)
-308,999
3.55
-87,042
-
Jul 27, 2023
titterton lewis h jr
acquired
309,000
2.575
120,000
-
Jul 20, 2023
catelani michael
bought
20,020
3.64
5,500
president, coo & cfo
Apr 28, 2023
catelani michael
acquired
3,001
3.47
865
president, coo & cfo
Oct 31, 2022
catelani michael
acquired
3,003
2.81
1,069
president, coo & cfo

1–10 of 50

Which funds bought or sold ANIX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
Concorde Asset Management, LLC
unchanged
-
9,430
59,981
0.04%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
168,326
168,326
-%
Feb 15, 2024
PARK CIRCLE Co
unchanged
-
305
1,940
-%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
sold off
-100
-68,670
-
-%
Feb 14, 2024
VANGUARD GROUP INC
added
2.2
947,721
5,404,480
-%
Feb 14, 2024
Royal Bank of Canada
added
3.04
2,000
5,000
-%
Feb 14, 2024
CITADEL ADVISORS LLC
reduced
-58.85
-67,903
64,777
-%
Feb 14, 2024
STATE STREET CORP
added
6.27
87,113
420,980
-%
Feb 14, 2024
GROUP ONE TRADING, L.P.
reduced
-19.54
-236
4,986
-%

1–10 of 43

Are Funds Buying or Selling ANIX?

Are funds buying ANIX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ANIX
No. of Funds

Unveiling Anixa Biosciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 16, 2024
kumar amit
13.5%
4,884,702
SC 13D/A
Sep 03, 2021
kumar amit
10.3%
3,423,112
SC 13D/A
Jun 10, 2021
kumar amit
8.6%
2,795,889
SC 13D/A
Feb 05, 2021
titterton lewis h jr
5.4%
1,445,326
SC 13D/A

Recent SEC filings of Anixa Biosciences Inc

View All Filings
Date Filed Form Type Document
Feb 08, 2024
DEF 14A
DEF 14A
Jan 16, 2024
SC 13D/A
13D - Major Acquisition
Jan 16, 2024
S-8
Employee Benefits Plan
Jan 16, 2024
4
Insider Trading
Jan 16, 2024
4
Insider Trading
Jan 16, 2024
4
Insider Trading
Jan 16, 2024
4
Insider Trading
Jan 16, 2024
4
Insider Trading
Jan 16, 2024
10-K
Annual Report
Dec 07, 2023
8-K
Current Report

Peers (Alternatives to Anixa Biosciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Anixa Biosciences Inc News

Latest updates
Yahoo Finance17 Feb 202402:03 pm

Anixa Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue---210,000180,000150,000120,00090,00060,00030,000--513,000410,400307,800205,200102,600--250,000125,000-
Costs and Expenses7.3%3,051,0002,844,0002,770,0002,556,0003,609,0002,797,0003,589,0003,880,0004,076,5004,388,0002,437,0002,746,0002,242,2272,435,9692,670,1372,629,8692,128,6312,184,4122,843,2344,983,7285,407,714
  S&GA Expenses-18.2%1,436,0001,756,0001,611,0001,488,0001,924,0001,352,0001,854,0002,042,0001,903,5002,221,0001,415,0001,533,0001,834,5311,181,8381,441,3471,139,2811,257,4431,056,9631,281,9662,066,4562,309,275
  R&D Expenses48.4%1,615,0001,088,000998,0001,068,0001,685,0001,445,0001,735,0001,838,0002,173,0002,167,0001,022,000828,000407,6961,254,1311,228,7901,490,588871,1881,085,5741,269,3932,247,2722,432,906
EBITDA Margin-143.8%-45.19-18.54-18.54-18.54-18.54-18.58-18.58-18.58-18.58-38.04-38.02-37.98---------
Interest Expenses---------3252772641,1349607,2668,45214,4681,94618,364---
Earnings Before Taxes----------------2,657,990-2,616,575-2,111,061-2,166,048-2,574,934-4,966,609-5,391,520
EBT Margin-143.8%-45.48-18.66-18.66-18.66-18.66-18.66-18.66-18.66-18.66-38.21-38.21-38.21---------
Net Income-7.1%-2,690,000-2,511,000-2,288,000-2,322,000-3,476,000-2,746,000-3,544,000-3,829,000-4,013,000-4,334,000-2,399,000-2,208,000-2,224,035-2,561,684-2,640,093-2,592,543-2,026,488-2,140,028-2,574,934-4,966,609-5,391,520
Net Income Margin-125.7%-46.72-20.70-21.16-23.61-26.55-27.60-30.70-28.47-25.30-44.66-37.57-38.54---------
Free Cashflow-36.3%-1,969,000-1,445,000-807,000-1,988,000-1,593,000-1,396,000-2,306,000-1,197,000-1,045,000-1,481,000-1,242,000-1,170,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-4.0%26.0027.0028.0028.0030.0033.0033.0035.0036.0037.0038.0015.009.009.006.009.006.007.008.006.006.00
  Current Assets-4.0%25.0026.0027.0028.0030.0032.0033.0035.0036.0037.0038.0015.009.009.006.006.006.007.007.006.006.00
    Cash Equivalents-71.4%1.003.006.0010.0012.0024.0028.0030.0029.0027.0028.0012.006.006.003.003.003.004.004.004.003.00
  Net PPE---------------0.000.000.000.000.000.000.00
Liabilities7.9%2.002.002.001.002.002.001.002.001.001.001.001.001.001.001.001.001.00----
  Current Liabilities9.2%2.002.002.001.002.001.001.002.001.001.001.002.001.001.001.001.001.001.002.001.001.00
Shareholder's Equity-4.6%24.0026.0026.0027.0029.0031.0031.0033.0035.0036.0037.0013.008.008.005.005.005.005.006.005.005.00
  Retained Earnings-1.2%-228-225-222-220-218-214-212-208-204-200-196-194-191-189-187-184-181-179-177-175-170
  Additional Paid-In Capital0.6%252251249248247246244242240237234207200198192190187185184180175
Accumulated Depreciation---------------0.000.000.000.000.000.000.00
Shares Outstanding0.4%31.0031.0031.0031.0031.0031.0030.0030.0030.0030.0031.0026.00---------
Minority Interest-3.3%-0.97-0.93-0.90-0.88-0.85-0.79-0.76-0.72-0.67-0.61-0.56-0.52-0.50-0.48-0.46-0.45-0.42-0.40-0.37-0.34-0.25
Float---121---93.00---140---35.00---72.00--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-36.3%-1,969-1,445-807-1,988-1,593-1,396-2,306-1,197-1,045-1,481-1,242-1,170-1,414-1,290-1,556-1,914-1,337-640-1,434-1,329-1,020
  Share Based Compensation0.3%1,1571,1531,1559571,0721,3301,4632,1352,6993,048881875---1,1101,021-9,294831-1,3212,750-14,122
Cashflow From Investing39.5%-593-980-3,444-585-9,917-2,9112501,8502,8071,000-8,399675500-520250-535-250650-1,175250743
Cashflow From Financing9200.0%2793.0081.003.00-384829--144-25,3616,0611,4034,8511,3731,7806825652,2802,176742

ANIX Income Statement

2023-10-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Income Statement [Abstract]  
Revenue$ 210
Operating costs and expenses:  
Inventor royalties, contingent legal fees, litigation and licensing expenses161
Research and development expenses (including non-cash share based compensation expenses of $2,037 and $3,635, respectively)4,7696,703
General and administrative expenses (including non-cash share based compensation expenses of $2,698 and $3,117, respectively)6,2917,172
Total operating costs and expenses11,22113,875
Loss from operations(11,011)(13,875)
Interest income1,081104
Net loss(9,930)(13,771)
Less: Net loss attributable to noncontrolling interest(119)(176)
Net loss attributable to common stockholders$ (9,811)$ (13,595)
Net loss per share:  
Basic$ 0.32$ 0.45
Diluted$ 0.32$ 0.45
Weighted average common shares outstanding:  
Basic30,98030,374
Diluted30,98030,374

ANIX Balance Sheet

2023-10-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Oct. 31, 2023
Oct. 31, 2022
Current assets:  
Cash and cash equivalents$ 915$ 12,360
Short–term investments22,92917,327
Receivables27046
Prepaid expenses and other current assets1,242467
Total current assets25,35630,200
Operating lease right-of-use asset166212
Total assets25,52230,412
Current liabilities:  
Accounts payable206265
Accrued expenses1,7701,726
Operating lease liability5246
Total current liabilities2,0282,037
Operating lease liability, non-current123175
Total liabilities2,1512,212
Equity:  
Preferred stock, value
Common stock, par value $.01 per share; 100,000,000 shares authorized; 31,145,219 and 30,913,902 shares issued and outstanding as of October 31, 2023 and 2022, respectively311309
Additional paid-in capital252,222247,123
Accumulated deficit(228,196)(218,385)
Total shareholders’ equity24,33729,047
Noncontrolling interest (Note 2)(966)(847)
Total equity23,37128,200
Total liabilities and equity25,52230,412
Series A Convertible Preferred Stock [Member]  
Equity:  
Preferred stock, value
ANIX
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
 CEO
 WEBSITEwww.anixa.com
 EMPLOYEES4

Anixa Biosciences Inc Frequently Asked Questions


What is the ticker symbol for Anixa Biosciences Inc? What does ANIX stand for in stocks?

ANIX is the stock ticker symbol of Anixa Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Anixa Biosciences Inc (ANIX)?

As of Thu Feb 22 2024, market cap of Anixa Biosciences Inc is 112.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANIX stock?

You can check ANIX's fair value in chart for subscribers.

What is the fair value of ANIX stock?

You can check ANIX's fair value in chart for subscribers. The fair value of Anixa Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Anixa Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Anixa Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether ANIX is over valued or under valued. Whether Anixa Biosciences Inc is cheap or expensive depends on the assumptions which impact Anixa Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANIX.

What is Anixa Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ANIX's PE ratio (Price to Earnings) is -11.5 and Price to Sales (PS) ratio is 537.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANIX PE ratio will change depending on the future growth rate expectations of investors.